Tech Transfer Roundup: MD Anderson Working To Unlock Promise Of Tumor-Infiltrating Lymphocytes
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
You may also be interested in...
Tech Transfer Roundup: Amylyx Goes Pipeline Hunting While Seeking US Approval Of ALS Candidate
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
CEO Exit Adds To Iovance Woes After Cell Therapy Setback
Iovance has a promising new cancer cell therapy on its hands, but another FDA query and the CEO’s departure has spooked investors.
Tech Transfer Roundup: MD Anderson Tackles Cancer In Alliances With UroGen, Xencor, Obsidian
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.